YA
Yangzhou Aurisco Pharmaceutical Co., Ltd. (Aurisco)
Manufacturer · Yangzhou, China
GMP
Overview
Aurisco Pharmaceutical was founded in 1998 and develops and makes generic and complex APIs and finished dosage forms, including peptides and oligonucleotides. Its Yangzhou site passed a US FDA pre-approval inspection in August 2026 for inclisiran sodium. Yangzhou Aurisco holds active US Type II DMFs for Semaglutide, Tirzepatide (3 DMFs in total).
Capabilities
- Peptide APIs (GLP-1)
- Oligonucleotide APIs
- Small-molecule APIs
- Finished dosage forms
Quality signals
| GMP evidence | Yes |
|---|---|
| Certificates of analysis | Not found |
| Third-party testing | Not found |
| ISO certification | Not found |
| Makes own product | Yes, in-house production |